Of interest is the finding of lower E2 levels in our study group versus the control group, as described previously by Almog et al. [9], despite the higher doses of recombinant FSH used in cancer patients, although this result is partly related to the use of aromatase inhibitors during ovarian stimulation in women with breast cancer. This evidence concerns the gene BRD2 and cancer.